Pfizer bets big on obesity drugs as post-pandemic revenue strategy

Pfizer is making a calculated bet that obesity will become the pharmaceutical industry's most reliable revenue engine for the next several decades—a market far more stable and enduring than the temporary windfall of pandemic vaccines and treatments.

The company revealed this ambition at the American Diabetes Association conference in New Orleans, where it presented fresh data on berobenatide, a long-acting GLP-1 injection acquired through Pfizer's $10 billion purchase of Metsera last year. In the latest trial results, patients receiving the highest weekly dose lost 15.9 percent of their body weight over eight months with no sign of plateauing. A separate analysis showed that when given monthly instead of weekly, the drug produced nearly 15 percent weight loss after 14 months. This dosing advantage matters enormously in a market currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both of which require weekly injections.

Pfizer's earlier stumbles in obesity treatment left the company trailing far behind its rivals. But executives now envision something far more ambitious than a single blockbuster drug. Chris Boshoff, the company's chief scientific officer, described the moment as "a new era of innovation in internal medicine." The pipeline extends well beyond weight loss itself. Pfizer plans major trials targeting conditions tightly linked to obesity—sleep apnea, knee osteoarthritis—and is launching large studies across China and Japan. The company is also pursuing even longer-acting formulations, with early data suggesting a compound that could be administered every three months rather than weekly or monthly.

The obesity market has already transformed the fortunes of Eli Lilly and Novo Nordisk, reshaping their entire business trajectories. Pfizer believes its scale, commercial expertise, and track record launching blockbuster drugs like Viagra and Lipitor position it to capture meaningful share. The company is not waiting passively. It acquired talent from Metsera and hired specialists to revitalize its internal research operations. It partnered with Shanghai Fosun Pharmaceutical's YaoPharma unit to develop an oral tablet after internal efforts stalled. It is testing its commercial infrastructure through a collaboration with Hangzhou Sciwind Bioscience in China, essentially running a pilot program before its own products reach American patients.

Manufacturing capacity may be Pfizer's sharpest advantage. While Lilly and Novo initially struggled to produce enough supply to meet demand, Pfizer already operates eight sterile injectable facilities worldwide. The company has internalized production of the Metsera drugs, moving them in-house from third-party manufacturers. Berobenatide requires far less active ingredient than competing drugs, potentially making it cheaper and easier to produce at scale. "We can manufacture these therapies at the scale required—and at a scale very few other companies can," Boshoff said.

Jim List, hired last year to lead Pfizer's internal medicine unit, frames obesity treatment as a natural fit for a company whose greatest successes—the cholesterol drug Lipitor, the blood thinner Eliquis—were built on deep relationships with primary care physicians and broad patient populations. As obesity treatment shifts from specialists into routine primary care, that infrastructure becomes increasingly valuable. "Primary care is in our DNA," List said.

Yet the competitive landscape is crowded and moving fast. Amgen is in advanced trials with a monthly injection, though early studies showed high rates of nausea; the company is testing lower starting doses to improve tolerability. Lilly and Novo already sell oral tablets that became enormously popular immediately upon launch. AstraZeneca and Structure Therapeutics are developing their own pill versions. Physicians say the next generation of obesity drugs must meaningfully outperform existing options—either through fewer side effects, greater convenience, or better treatment of related conditions.

Pfizer is running ten major pivotal trials for berobenatide alone in 2026, and that represents less than half of its broader obesity program. Even if everything proceeds smoothly, years will pass before the drug reaches patients. The company's executives argue that winning in obesity will require more than a single successful medication. It will demand speed, manufacturing prowess, and the ability to persuade patients, doctors, and insurers to adopt new treatments. Boshoff has already begun imagining a future where obesity treatment becomes highly individualized—tailored to genetics, biomarkers, patient preferences, and specific complications, much as cancer care has evolved over the past two decades. That vision, if realized, would lock in Pfizer's position for generations.